Key clinical point: Anthracycline+taxane-based regimens demonstrated significantly higher improvement in survival outcomes than non-anthracycline-containing taxane-based regimens in patients with triple-negative breast cancer (TNBC) who were ≥76 years old and had ≥4 positive lymph nodes.
Major finding: Although anthracycline+taxane-based vs taxane-based regimens failed to improve cancer-specific survival (CSS) in the overall cohort of older patients with TNBC (hazard ratio [HR] 0.94; P = .79); they improved CSS in patients aged ≥76 years with ≥4 positive lymph nodes (HR 0.09; P = .02).
Study details: Findings are from a retrospective analysis of 1106 women aged ≥66 years with node-positive TNBC from the Surveillance, Epidemiology, and End Results-Medicare database, of which 661 women received adjuvant chemotherapy with anthracycline+taxane-based regimens (n = 364) or taxane-based regimens (n = 297).
Disclosures: This study was funded by the Women’s Cancer Developmental Therapeutics Program, University of Colorado Cancer Center. The authors declared no conflicts of interest.
Source: Roy S et al. Clinical outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 (Feb 27). Doi: 10.1016/j.ejca.2023.02.014